Brain metastases are the most common malignancy encountered in the central nervous
system (CNS), with up to 30-40% of cancer patients developing brain metastases at some …

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) bring significant
benefits to non-small cell lung cancer patients with EGFR mutations, which represent a …

Introduction Management of central nervous system (CNS) metastases in patients with driver-
mutated NSCLC has traditionally incorporated both tyrosine kinase inhibitors (TKIs) and …

Central nervous system (CNS) metastases are common in non-small-cell lung cancer
(NSCLC) and associated with poor prognosis and high disease burden. Effective options …

Purpose As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI), osimertinib has a powerful ability to penetrate the blood-brain barrier and a …

Simple Summary In the multi-modal treatment of brain metastasis (BM), the role of systemic
therapy has undergone a recent revolution. Due to the development of multiple agents with …

Background and purpose To analyze outcomes of non-small cell lung cancer (NSCLC)
patients with brain metastases harboring EGFR or ALK mutations and examine for …

Tyrosine kinases are known to play a role in tumour growth and proliferation, and they have
become common drug targets. Tyrosine kinase inhibitors (TKIs) prohibit associated kinases …

Importance Intracranial metastatic disease (IMD) is a serious and life-altering complication
for many patients with cancer. Targeted therapy may address the limitations of current …

Stereotactic radiosurgery (SRS) is a standard option for brain metastases (BM). There is lack
of consensus when patients have a systemic treatment, if a washout is necessary. The aim of …